Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
Inogen Inc. (INGN) is a pioneering medical technology company committed to enhancing the quality of life for supplemental oxygen users. Founded in 2001, Inogen emerged from a personal story of necessity and innovation. The company's mission began when Mae, the grandmother of one of the founders, was prescribed oxygen therapy, highlighting the need for more user-friendly and portable oxygen solutions. You can learn more about Mae's story here.
Inogen aims to revolutionize oxygen therapy technology, striving to keep pace with the active lifestyles of patients who rely on oxygen to lead fulfilling lives. The company estimates that over 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy.
The company's flagship product, the Inogen One system, is a compact, lightweight, and travel-approved portable oxygen concentrator designed to liberate patients from the constraints of heavy tanks, frequent refills, and stationary systems. This innovation provides patients with the freedom and independence to live their lives by moments, not by the minutes left in an oxygen tank.
Inogen's products and services are sold through various channels, including home medical equipment providers, distributors, large gas companies, and home oxygen providers. The company also rents its products directly to patients, generating the majority of its revenue within the United States.
Inogen's commitment to continuous improvement is evident in its ongoing projects and recent achievements. The company constantly works toward refining its product offerings and expanding its reach to benefit more patients globally.
Inogen, Inc. (NASDAQ: INGN) has announced the appointment of Dr. Stanislav Glezer as Chief Technology Officer, overseeing R&D, Medical Affairs, and Regulatory Affairs. Dr. Glezer, who joined Inogen in June 2021, brings over 27 years of experience in medical technology. He replaces Brenton Taylor, who will transition out by April 1, 2022. CEO Nabil Shabshab praised Dr. Glezer for his contributions in enhancing product development and market strategies. The management changes are expected to drive innovation and shareholder value, with a focus on improving patient outcomes.
Inogen, Inc. (NASDAQ: INGN) has announced a partnership with Ashfield Healthcare to enhance its sales capabilities by adding around 20 dedicated sales representatives to its prescriber sales organization. The collaboration aims to improve market penetration for portable oxygen concentrators (POCs) and leverage Ashfield's proprietary insights and analytics tools to drive clinician sales performance. CEO Nabil Shabshab emphasized the importance of increasing collaboration with healthcare prescribers to enhance awareness of Inogen’s offerings. This strategy is expected to positively impact patient service in oxygen therapy.
Inogen, Inc. (NASDAQ: INGN) reported a 41.7% increase in second-quarter 2021 revenue, reaching $101.6 million, driven by strong consumer demand and improved pricing. Domestic direct-to-consumer revenue rose 35.6% to $40.9 million, while rental revenue soared 85.2% to $11.3 million. However, the company faces supply chain challenges, particularly due to semiconductor shortages, which are expected to constrain revenue growth and increase costs. As of June 30, 2021, Inogen had $250 million in cash with no debt and anticipates a net loss in the second half of 2021 due to these challenges.
Inogen, Inc (Nasdaq: INGN) will release its second quarter 2021 financial results on August 4, 2021, after market close. A conference call will follow at 1:30pm PT/4:30pm ET to discuss the results. Interested participants can join by calling (877) 841-3961 for domestic or (201) 689-8589 for international access. A replay will be available from August 4, 2021, 3:30pm PT until August 18, 2021. The company focuses on developing and marketing portable oxygen concentrators for chronic respiratory patients.
Inogen has appointed Jason Somer as the new Executive Vice President and General Counsel, effective July 12, 2021. CEO Nabil Shabshab emphasized that Somer's 25 years of legal experience will enhance Inogen's legal and compliance functions, crucial for the company's growth strategy. Somer expressed his commitment to increasing stockholder value while leading the legal organization. His previous roles include serving as head legal counsel at Invoca, and he holds advanced degrees in law and biology.
Inogen, Inc. (NASDAQ: INGN) has appointed Dr. Stanislav Glezer as Executive Vice President and Chief Medical Officer, effective June 21, 2021. CEO Nabil Shabshab expressed confidence that Dr. Glezer's over 25 years of experience in clinical research and medical affairs will enhance Inogen's clinical capabilities and market development efforts. Dr. Glezer aims to lead Medical Affairs, Clinical Research, and Regulatory organizations to improve patient outcomes through clinical evidence collaboration. His previous roles include significant positions at Becton, Dickinson and Company, and Novo Nordisk.
Inogen, a medical technology company, has appointed Elizabeth (Beth) Mora to its Board of Directors, effective May 24, 2021. Mora, a seasoned executive with extensive financial expertise, fills the vacancy left by R. Scott Greer, who resigned from the board. She will also serve on the Audit Committee. CEO Nabil Shabshab expressed confidence in Mora's ability to enhance strategic initiatives aimed at increasing patient access to oxygen therapy products. The board transition aims to strengthen governance and support Inogen's growth objectives, scheduled for review at the 2024 annual meeting.
Inogen, Inc. (NASDAQ: INGN), a leader in respiratory health technologies, will present at the 41st Annual William Blair Virtual Growth Stock Conference on June 3rd, 2021, at 4:00 p.m. CDT. CEO Nabil Shabshab and CFO Alison Bauerlein will lead the presentation, which can be accessed via the company's Investor Relations page. This presentation highlights Inogen's commitment to innovation in portable oxygen concentrators, enhancing care options for patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) reported Q1 2021 revenue of $86.9 million, a 1.8% decline from Q1 2020, largely due to COVID-19 impacts. Domestic business-to-business revenue rose 11.6% to $30.7 million, while rental revenue surged 84.2% to $9.9 million. As of March 31, 2021, cash and equivalents totaled $233.2 million, with no debt. Operating loss was $2.1 million, and net loss was $0.7 million. The company refrained from providing full-year guidance for 2021 due to pandemic uncertainties, while anticipating increased operational expenses as it invests in growth initiatives.
Inogen, a medical technology company focused on respiratory products, will announce its first quarter 2021 financial results on May 4, 2021, after market close. A conference call will follow at 1:30 PM PT/4:30 PM ET, with a replay available until May 18, 2021. Investors can listen live via phone or through Inogen's Investor Relations website. The company specializes in portable oxygen concentrators for patients with chronic respiratory conditions.
FAQ
What is the current stock price of Inogen (INGN)?
What is the market cap of Inogen (INGN)?
What does Inogen Inc. do?
What is Inogen's flagship product?
How does Inogen sell its products?
Where does Inogen generate most of its revenue?
How many patients use oxygen therapy according to Inogen?
What makes Inogen's products stand out?
What is the mission of Inogen Inc.?
Who inspired the founding of Inogen?
Where can I learn more about Inogen's history?
What is Inogen Inc.'s stock symbol?
